Overview


According to FutureWise analysis the market for endometriosis treatment in 2023 is US$ 1.36 billion, and is expected to reach US$ 3.82 billion by 2031 at a CAGR of 13.72%.

Rise in the female population within the reproductive age, growing awareness amongst women regarding the disease, the availability of novel drugs for treating endometriosis are some of the factors contributing to the growth of the market. Endometriosis is very painful and can result into infertility. It affects the outlined tissues of the uterus and causes internal bleeding and inflammation.

However, it takes over seven years to even diagnose the disease and the unavailability of non-invasive diagnostic tests shall increase the patient’s suffering. Therefore, this factor shall possibly restrain the endometriosis treatment market growth. Furthermore, many key market players are conducting extensive researches in developing advanced drugs and treatment methodologies for endometriosis keeping cost management into consideration. Such initiatives undertaken by major market players shall propel the market growth.

  • Eli Lilly and Company
  • AstraZeneca Plc.
  • Bayer AG
  • Astellas Pharma
  • Abbvie
  • Meditrina Pharmaceuticals
  • Pfizer Inc.
  • Neurocrine Biosciences Inc.
  • Takeda Pharmaceutical Company.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type

  • Progestin
  • Gonadotropins Releasing Hormone Agonists
  • Oral Contraceptive Pills
  • Non-Steroidal Anti-Inflammatory Drugs

By Distribution Channel

  • Pain Management
  • Hormonal Therapies

By Treatment Type

  • Drug Stores
  • Hospital Pharmacies
  • Mail Order Pharmacies
  • E-Pharmacies
  • Retail Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The market is categorised into drug type, distribution channel, treatment type and region. The drug type segment is bifurcated into progestin, gonadotropins releasing hormone agonists, oral contraceptive pills, non-steroidal ani-inflammatory drugs. The oral contraceptive pills segment is predicted to account the largest endometriosis treatment market share as it is a highly preferred treatment method owing to their efficacy of preventing the recurrence of endometriosis lesions and pelvic pain. But there are side effects of these pills like mood swings, elevated blood pressure and nausea. The progestins are required to be consumed intermittently unlike oral contraceptives that should be consumed regularly. The treatment segment is fragmented into pain management and hormonal therapies. The distribution channel segment is bifurcated into drug stores, hospital pharmacies, mail order pharmacies, e-pharmacies, retail pharmacies and others.

The North America region is predicted to dominate the market during the forecast period and this can be credited to the rising population capable of reproducing, increased patient number diagnosed with endometriosis, high losses owing to disability and key market players have a stronghold in the region. The Asia Pacific region, on the other hand, is predicted to grow at a substantial rate during the forecasted timeframe owing to key market players expanding their businesses in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global endometriosis treatment market by drug type, by distribution channel, by treatment type and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Endometriosis Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Endometriosis Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Endometriosis Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Endometriosis Treatment Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Progestin
        2. Gonadotropins Releasing Hormone Agonists
        3. Oral Contraceptive Pills
        4. Non-Steroidal Anti-Inflammatory Drugs

  • 8.   Endometriosis Treatment Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Pain Management
        2. Hormonal Therapies

  • 9.   Endometriosis Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Drug Stores
        2. Hospital Pharmacies
        3. Mail Order Pharmacies
        4. E-Pharmacies
        5. Retail Pharmacies
        6. Others

  • 10.   North America Endometriosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Endometriosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Endometriosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Endometriosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Eli Lilly and Company
         1.1. Company Overview (HQ, Business Segments, Employee Strength)
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AstraZeneca Plc.
         2.1. Company Overview (HQ, Business Segments, Employee Strength)
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bayer AG
         3.1. Company Overview (HQ, Business Segments, Employee Strength)
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Astellas Pharma
         4.1. Company Overview (HQ, Business Segments, Employee Strength)
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Abbvie
         5.1. Company Overview (HQ, Business Segments, Employee Strength)
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Meditrina Pharmaceuticals
         6.1. Company Overview (HQ, Business Segments, Employee Strength)
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer Inc.
         7.1. Company Overview (HQ, Business Segments, Employee Strength)
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Neurocrine Biosciences Inc.
         8.1. Company Overview (HQ, Business Segments, Employee Strength)
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Takeda Pharmaceutical Company
         9.1. Company Overview (HQ, Business Segments, Employee Strength)
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients